It was demonstrated that the expression profile of serine/glycine metabolic pathway is unique to the molecular subtype of breast cancer, with high activity in HER-2 [56] and triple negative types [57], which is correlated with poor clinical prognosis [58]. Here, ERBB2 is linked to breast cancer.